Roche immunotherapy combination increases lung cancer survival - study

(Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

ConclusionsBoth treatment strategies produce equivalent and better than expected outcomes compared to historical controls for N2 NSCLC, with no differences in recurrence patterns. How these conventional therapeutic strategies will compare to those involving immunotherapy combined with surgical loco-regional disease control for N2 disease remains to be determined.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
CONCLUSIONS: Both treatment strategies produce equivalent and better than expected outcomes compared to historical controls for N2 NSCLC, with no differences in recurrence patterns. How these conventional therapeutic strategies will compare to those involving immunotherapy combined with surgical loco-regional disease control for N2 disease remains to be determined. PMID: 30227129 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research
Authors: Qin H, Wang F, Liu H, Zeng Z, Wang S, Pan X, Gao H Abstract Immunotherapy is one of the methods that can change the survival rate of patients with malignant tumors, in addition to surgery therapy, radiotherapy, chemotherapy and targeted therapy. Among various immunotherapy methods, immunoprecipitation inhibitors have been the most effective medications developed in recent years. At present, more in-depth studies have been conducted for two immune checkpoint inhibitor pathways, programmed cell death protein 1 (PD-1)/Programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), ...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Condition:   Small Cell Lung Cancer Intervention:   Drug: Combination immunotherapy with Ipilimumab and Nivolumab Sponsors:   Yale University;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This article summarizes the latest clinical trials concerning the use of radiotherapy, chemotherapy, molecularly targeted therapies and immunotherapy in lung cancer patients, with particular consideration of brain lung cancer metastasis prevention. The literature search was undertaken via PubMed and EMBASE searches and relevant articles are included in this review. Expert Commentary: The recent data supports that EGFR-TKIs and ALK inhibitors are clinically relevant for first-line treatment to prevent and treat CNS metastases in molecularly-selected NSCLC patients. In the future, high hopes for the prevention of CNS metasta...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
CONCLUSIONS: A quarter of patients treated by chemotherapy for a lung cancer in Reunion consume graviola regularly as self medication. The consequences of this intake, drug interactions and side effects are unknown and would be interesting to identify. PMID: 30195454 [PubMed - as supplied by publisher]
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
Conclusions: In very lethal non-small cell lung cancer subtypes such as the sarcomatoid variants, high tumor burden and deteriorated general conditions should not preclude, at least in some cases, the use of immunotherapy. Anti-PD1 may also have a reliable role in disease control in the brain. Lastly, the strong rationale behind sarcomatoid histology should further prompt trials exploring immunotherapeutic approaches in this subset of non-small cell lung cancer.Case Rep Oncol 2018;11:615 –621
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Cancer is never an easy foe, but some types are more stubborn than others. Ovarian cancer is one of the hardest to treat. But there are signs of progress. Several recent studies have used new combination treatment strategies, including a drug that may make chemotherapy more effective and a drug originally designed to treat breast cancer. More research is needed, but the new studies provide hope for improving outcomes for women with advanced ovarian cancer, when there was little before. On its face, ovarian cancer isn’t actually more difficult to treat than other cancers like breast, prostate or lung. It is, technical...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer healthytime Innovation Health Source Type: news
AbstractOsimertinib is the best treatment choice for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) whose disease progresses on a first- or second-generation EGFR-tyrosine kinase inhibitor due to acquired T790M mutation. On the other hand, there is a lack of therapeutic strategies with proven efficacy at the time of progression on osimertinib. If not administered previously, platinum-based chemotherapy can provide some clinical benefit, while immunotherapy does not seem to work in this setting. Here, we report on a unique case of response to osimertinib rechallenge...
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Health | Immunotherapy | Lung Cancer | Study